Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Yiran Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1965-8414; OpenAlex author ID A5013716235. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2019: 3 papers · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 4 papers · 2024: 1 paper

Papers 10

  1. ROCK1 regulates glycolysis in pancreatic cancer via the c-MYC/PFKFB3 pathway. Last author DOI 10.1016/j.bbagen.2024.130669↗
  2. Risk factors for and prognostic values of postoperative acute kidney injury after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: A retrospective… First author DOI 10.1002/cam4.5543↗
  3. Health-related quality of life and survival outcomes for patients with major depressive disorder and anxiety: A longitudinal study in pancreatic ductal adenoca… Co-author DOI 10.1002/cam4.6577↗
  4. TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-023-04742-y↗
  5. The Impact of Additional Para-aortic Dissection During Pancreaticoduodenectomy for Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-12700-z↗
  6. LncRNA SNHG7 Regulates Mesenchymal Stem Cell Through the Notch1/Jagged1/Hes-1 Signaling Pathway and Influences Folfirinox Resistance in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.719855↗
  7. Inhibitory effects of canagliflozin on pancreatic cancer are mediated via the downregulation of glucose transporter‑1 and lactate dehydrogenase A. First author DOI 10.3892/ijo.2020.5120↗
  8. Polysaccharide enhanced NK cell cytotoxicity against pancreatic cancer via TLR4/MAPKs/NF-κB pathway in vitro/vivo. Co-author DOI 10.1016/j.carbpol.2019.115223↗
  9. Should a standard lymphadenectomy include the No. 9 lymph nodes for body and tail pancreatic ductal adenocarcinoma? Co-author DOI 10.1016/j.pan.2019.03.005↗
  10. LncRNA SNHG7 promotes pancreatic cancer proliferation through ID4 by sponging miR-342-3p. Co-author DOI 10.1186/s13578-019-0290-2↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Baiyong Shen · 6 shared papers, 2019–2023 · strength 0.94
  2. Yuchen Ji · 4 shared papers, 2023 · strength 0.74
  3. Xiaxing Deng · 4 shared papers, 2019–2023 · strength 0.64
  4. Haoda Chen · 3 shared papers, 2023 · strength 0.57
  5. Dongfeng Cheng · 4 shared papers, 2019–2023 · strength 0.51
  6. Kai Qin · 3 shared papers, 2019–2023 · strength 0.41
  7. Shuyang Pang · 2 shared papers, 2020–2024 · strength 0.38
  8. Ziyun Shen · 2 shared papers, 2023 · strength 0.38
  9. Jiabin Jin · 2 shared papers, 2021–2023 · strength 0.31
  10. Chenghong Peng · 2 shared papers, 2019–2023 · strength 0.27
  11. Xuanning Chu · 1 shared paper, 2024 · strength 0.26
  12. Jingrui Yang · 2 shared papers, 2019–2021 · strength 0.25
  13. Duiyue Xu · 2 shared papers, 2019–2020 · strength 0.22
  14. Changlin Zhou · 2 shared papers, 2019–2020 · strength 0.22
  15. Shulin Zhao · 1 shared paper, 2023 · strength 0.20
  16. Hongzhe Li · 1 shared paper, 2023 · strength 0.19
  17. Weishen Wang · 1 shared paper, 2023 · strength 0.17
  18. Yuanchi Weng · 1 shared paper, 2023 · strength 0.17
  19. Jun Zhang · 1 shared paper, 2023 · strength 0.17
  20. Yu Jiang · 1 shared paper, 2023 · strength 0.17
  21. Ningzhen Fu · 1 shared paper, 2023 · strength 0.17
  22. Jun Wang · 1 shared paper, 2023 · strength 0.17
  23. Baiyong Shen · 1 shared paper, 2020 · strength 0.12
  24. Jiewei Lin · 1 shared paper, 2019 · strength 0.10
  25. Xin Xie · 1 shared paper, 2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.